Similar articles

• Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group.

  Reiffers J, Stoppa AM, Rigal-Huguet F, Michallet M, Marit G, Gastaut JA, Attal M, Corront B, Broustet A, Hollard D, et al. Reiffers J, et al. Bone Marrow Transplant. 1991;7 Suppl 2:36. Bone Marrow Transplant. 1991. PMID: 1878709 Clinical Trial. No abstract available.
• Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.

  Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, Huguet F, Corront B, Cony-Makhoul P, Gastaut JA, Laurent G, Molina L, Broustet A, Maraninchi D, Pris J, Hollard D, Faberes C. Reiffers J, et al. Leukemia. 1996 Dec;10(12):1874-82. Leukemia. 1996. PMID: 8946925 Clinical Trial.
• The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).

  Weinstein H, Ravindranath Y, Krischer J, Steuber P, Civin C, Gresik M, Vietti T. Weinstein H, et al. Leukemia. 1992;6 Suppl 2:52-4. Leukemia. 1992. PMID: 1578941 Clinical Trial. No abstract available.
• Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.

  Stone RM, Mayer RJ. Stone RM, et al. Hematol Oncol Clin North Am. 1993 Feb;7(1):47-64. Hematol Oncol Clin North Am. 1993. PMID: 8449864 Review.
• Optimal induction and post-remission therapy for AML in first remission.

  Rowe JM. Rowe JM. Hematology Am Soc Hematol Educ Program. 2009:396-405. doi: 10.1182/asheducation-2009.1.396. Hematology Am Soc Hematol Educ Program. 2009. PMID: 20008225 Review.